Christopher Cronsell, MD
Physical Medicine & Rehabilitation · Milwaukee, WINPI 1831212109
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $270,809 of the $352,839 with a category attached, or 76.8%. AbbVie accounts for 84.3% of it on its own, with 34 other manufacturers making up the rest. Among physical medicine & rehabilitation clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $532.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$297K
- Piramal Critical Care$49K
- Novartis$1K
- Pacira Pharmaceuticals Incorporated$951
- Genentech USA, Inc.$635
- Ipsen Biopharmaceuticals, Inc$514
- plus $3K from 29 others
Across 52 payments — averaging $7579.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$332K
- Ipsen Innovation$43K
- Pacira Pharmaceuticals Incorporated$20K
What the payments were for
- Consulting fees$51,65015%
- Speaking & faculty fees$270,80977%
- Travel & lodging$18,9835%
- Food & beverage$11,2943%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 268 | $297,331 |
| Piramal Critical Care | 88 | $48,859 |
| Novartis | 66 | $1,218 |
| Pacira Pharmaceuticals Incorporated | 8 | $951 |
| Genentech USA, Inc. | 50 | $635 |
| Ipsen Biopharmaceuticals, Inc | 17 | $514 |
| Lundbeck LLC | 20 | $438 |
| Biogen | 16 | $328 |
| Merz Pharmaceuticals, LLC | 9 | $326 |
| TG Therapeutics, Inc. | 9 | $261 |
| Teva Pharmaceuticals USA, Inc. | 24 | $240 |
| Bristol Myers Squibb | 18 | $237 |
| Pfizer | 10 | $212 |
| E.r. Squibb & Sons, L.L.C. | 13 | $178 |
| Revance Therapeutics, Inc. | 3 | $148 |
| AstraZeneca | 7 | $137 |
| Amgen(2 entities) | 6 | $120 |
| Grifols USA, LLC | 4 | $77 |
| US Oncology Corporate, Inc. | 1 | $67 |
| Lilly USA, LLC | 4 | $61 |
| Microtransponder, Inc. | 1 | $57 |
| Sanofi | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Octapharma USA, Inc. | 2 | $38 |
| UCB, Inc. | 1 | $34 |
| Acorda Therapeutics, Inc | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| EMD Serono, Inc. | 1 | $28 |
| Argenx US, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$352,839 in reported general payments places this provider in the 95th percentile of 207 physical medicine & rehabilitation providers in Wisconsin.
See all physical medicine & rehabilitation providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 13 | $118,131 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $23,001 |
| UbrelvyUbrogepant | 19 | $19,733 |
| QuliptaAtogepant | 11 | $11,985 |
| Sumatriptan Succinate | 46 | $5,144 |
| Baclofen | 94 | $2,341 |
| Tizanidine Hcl | 50 | $730 |
| Teriflunomide | 12 | $588 |
| Gabapentin | 19 | $470 |
| Cyclobenzaprine Hcl | 21 | $403 |
| RizatriptanRizatriptan Benzoate | 23 | $238 |
| Pregabalin | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $328 | $118,13113 claims |
| AbbVieUbrelvy, Qulipta | $297,331 | $31,71830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 physical medicine & rehabilitation providers in Wisconsin.
Other physical medicine & rehabilitation in Milwaukee
- Nicholas KetchumMilwaukee$573K
- Karin GoodfriendMilwaukee$191K
- John McGuireMilwaukee$75K
- Erin McGonigleMilwaukee$66K
- Noelle LiskaMilwaukee$13K
- Trinh TruongMilwaukee$11K
- Bindiya ShahMilwaukee$10K
- Salman AljilaniMilwaukee$4K
- Lori BrooksMilwaukee$4K
- Carla WrightMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.